JOA - 2026-11-06 - Journal Article
Postoperative Skeletal Muscle Relaxants and Risk of Periprosthetic Fracture After Total Hip Arthroplasty.
Wertz S, Sells P, Shen V, Durbin J, Cui E, Winthrop I, Norris Z, Ranson R, Sterling R
Topics
Key Takeaway
Postoperative skeletal muscle relaxant use within 30 days of THA is associated with up to 8.06-fold increased odds of periprosthetic fracture in SMR-naive osteoarthritis patients.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study used a large national database to determine whether postoperative SMR prescription within 30 days of THA increases periprosthetic fracture risk, stratifying by indication (OA vs. femoral head/neck fracture) and prior SMR exposure (naive vs. chronic). In OA patients, naive SMR use carried OR 8.06 (95% CI 5.39–12.03) and chronic use OR 4.41 (95% CI 2.68–7.26) for 30-day PPFx. In femoral head/neck fracture patients, naive use yielded OR 2.36 (95% CI 1.17–4.83) and chronic use OR 2.75 (95% CI 1.48–5.08), with increased reoperation rates in both groups.
Key Limitation
The database design cannot confirm whether SMR use preceded a fall that caused the fracture, making causal directionality between SMR prescription and PPFx unverifiable.
Original Abstract
INTRODUCTION
Skeletal muscle relaxants (SMR) are often prescribed postoperatively following total hip arthroplasty (THA). These medications can increase fall risk by causing drowsiness and sedation. This study seeks to explore the association between postoperative SMR use and periprosthetic fracture (PPFx). We hypothesized that postoperative SMR use would be associated with increased odds of PPFx and that this association would be stronger among SMR-naive users.
METHODS
A large national database was used to identify adult patients who underwent THA for either femoral head or neck fracture (FHNFx) or osteoarthritis (OA) from 2011 to 2025. Patients were stratified into two cohorts based on whether they were prescribed an SMR in the first postoperative month. Patients who were not prescribed a postoperative SMR served as controls. The experimental cohort was further stratified into naive or chronic SMR users based on the absence or presence of an SMR prescription within six months prior to surgery. The primary outcomes were 30-day odds of PPFx and reoperation.
RESULTS
Both naive and chronic postoperative SMR use were associated with increased 30-day odds of PPFx following THA in FHNFx patients (naive: odds ratio (OR) 2.36, 95% confidence interval (CI) [1.17 to 4.83], P = 0.013; chronic: OR 2.75, 95% CI [1.48 to 5.08], P = 0.001) and OA patients (naive: OR 8.06, 95% CI [5.39 to 12.03]; chronic: OR 4.41, 95% CI [2.68 to 7.26]; P < 0.001 for both).
DISCUSSION
Prescription of SMR after THA is associated with greater 30-day odds of PPFx and reoperation following THA, with the strongest association observed in naive OA patients. Surgeons should carefully weigh the risks and benefits of postoperative SMR use.